TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03772496

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: circulating tumor cells test
Description: 10 ml Peripheral blood are drawn from patients enrolled before surgery/FNAB and centrifuged to collect the peripheral blood mononuclear cells. Then, negative and positive immunomagnetic selections are used to exclude white blood cells and enrich tumor cells. After isolating mRNA, RT-PCR array is used to measure expression of target genes.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fine needle aspiration biopsy
Description: patients with potential malignant thyroid nodules are performed fine needle aspiration biopsy with the aid of ultrasound. The result of FNAB were classified by Bethesda rating system.
Study: NCT02253797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-Tipranavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Study: NCT04010331

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nokyong Mixture Extract(CME-PI)
Description: 2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 8 week
Study: NCT02899338

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI695501 Prefilled syringe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI695501Autoinjector
Study: NCT00322257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled human insulin
Description: Treat-to-target dose titration scheme, inhalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Injection s.c., 50% of daily dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: Injection s.c., 50% of daily dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Treat-to-target dose titration scheme, injection s.c.
Study: NCT03585530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltitrexed
Description: Raltitrexed 2.6mg/m2 was administered on d1、d22
Study: NCT04351516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: dose of 600mg on the first day followed with 400mg/day divided in 2x200mg for 6 more days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: Film Coated Tablette
Study: NCT04570904

Intervention type: BIOLOGICAL
Intervention: Influenza vaccination at different time points
Description: All HCWs will receive the seasonal influenza vaccine but at two different time points.

Intervention type: BIOLOGICAL
Intervention: Influenza vaccination at different time points
Description: All HCWs will receive the seasonal influenza vaccine but at two different time points.
Study: NCT01184196

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Swab area with Betadine
Description: A swab will be taken over the operative knee before surgical site preparation is started, after preparation has taken place, and 24 hours post-surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Swab area with ChloraPrep
Description: A swab will be taken over the operative knee before surgical site preparation is started, after preparation has taken place, and 24 hours post-surgery.
Study: NCT03133364

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sensory optimized meals
Description: 19 main meals and 12 between-meals are optimized and composed to a menu for 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sensory optimized meals
Description: 19 main meals and 12 between-meals are optimized and composed to a menu for 12 weeks.
Study: NCT02272777

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: Imatinib 400mg QD，300mg QD or 600mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Nilotinib 300mg BID or 400mg QD
Study: NCT04529746

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EVERYbody Project
Description: Brief behavioral intervention (4 hours across two meetings)
Study: NCT02804737

Intervention type: DEVICE
Intervention: Aiddly (Web Site)
Description: A website designed to better educate patients on how to prepare for their colonoscopies
Study: NCT02992678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Pentoxifylline, 400 mg, 3 times daily by mouth the day before ERCP procedure. Subjects received up to a maximum of 3 doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 400 mg, 3 times daily by mouth by mouth the day before ERCP procedure. . Subjects received up to a maximum of 3 doses.
Study: NCT00006734

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT02829970

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SUCCEEDS Program
Description: Participants will receive ADHD Psychoeducation, Brief Motivational Interviewing (BMI) and Behavioral Activation for Attention \& Alcohol Disorders (BAAAD).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Living a Healthy College Lifestyle
Description: Participants will receive ADHD Psychoeducation, BMI and Supportive Counseling (SC).
Study: NCT01658293

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: thermal stimulation
Description: The heat and cold-water will be added to the thermal group for 30-40minutes a session daily,five sessions a week for six weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control group ergometer exercises
Description: The control group will be given ergometer exercises with the similar duration as experimental group.
Study: NCT00167505

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Avoidance Intervention
Description: The risk avoidance intervention is a Title V compliant curriculum emphasizing abstinence until marriage and strong character development. The curriculum includes 12 classroom and CD-ROM based lessons delivered in the 7th and 8th grade. Lessons include topics such as puberty, reproduction, healthy relationships, consequences of sex, and refusal skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Reduction Intervention
Description: The risk reduction intervention is a curriculum providing skills for abstinence and condom and other contraceptive use. The curriculum includes 12 classroom and CD-ROM based lessons delivered in the 7th and 8th grade. Lessons include topics such as puberty, reproduction, healthy relationships, consequences of sex, and refusal skills.
Study: NCT01174134

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional beverage

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nutritional beverage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional beverage
Study: NCT00156247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acitretin
Description: Patients who have been taking etanercept 50 mg/week for at least 3 months (12 weeks) will take acitretin 25 mg pill once daily for 6 months.
Study: NCT03748082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Inhaled nitric oxide (iNO) will be administered via the CPB machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the ICU. Test gas administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, iNO will be weaned and discontinued.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Reactive Hyperemia Index
Description: Vascular responsiveness will be assessed with peripheral arterial tonometry which measures the transient increase in forearm blood flow (Reactive Hyperemia Index, RHI) in response to a five-minute occlusion of the brachial artery with a pressure cuff.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Reactive Hyperemia Index
Description: Vascular responsiveness will be assessed with peripheral arterial tonometry which measures the transient increase in forearm blood flow (Reactive Hyperemia Index, RHI) in response to a five-minute occlusion of the brachial artery with a pressure cuff.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Endothelial Cells Collection
Description: Endothelial cells are collected before and after surgery from a peripheral vessel using a soft J-shaped wire inserted through an intravascular catheter.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endothelial Cells Collection
Description: Endothelial cells are collected before and after surgery from a peripheral vessel using a soft J-shaped wire inserted through an intravascular catheter.
Study: NCT06354504

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment
Description: Scaling and root planing in two sessions over the course of a 48-hour period comprised the standard treatment procedure
Study: NCT00886171

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Skills Training
Description: Social skills group will consist of one session (60 minutes) per week for 8 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Training
Description: Physical activity groups consist of one session (60 minutes) per week for 8 weeks
Study: NCT02218411

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Exercises routine based on the Otago exercise programme
Study: NCT02738242

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novus system
Description: The Novus system is a FES based neuroprosthesis, which intended to provide ankle dorsiflexion and knee flexion or extension in individuals with foot drop and thigh muscle weakness, following an upper motor neuron injury or disease.
Study: NCT00649025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FlutiForm 250/10
Description: SKP FlutiForm 250/10ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SKP-Fluticasone
Description: SKP Fluticasone 250 ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flovent Fluticasone HFA
Description: Flovent 250 ug HFA is a pMDI that delivers after priming 125ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
Study: NCT01483352

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accu-Chek DiaPort
Study: NCT04200417

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chemoembolization
Description: Chemoembolization will be performed via the artery (bronchial, non-bronchial systemic, or pulmonary) that shows the greatest tumor enhancement on angiography. Chemoembolization will be performed using a lipiodol / mitomycin emulsion, followed by spherical particles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Description: Mitomycin (5mg/m\^2,maximum mitomycin dose 20 mg) will be dissolved in lipiodol at 2 mg/ml on the day of procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipiodol
Description: Mitomycin (5mg/m\^2,maximum mitomycin dose 20 mg) will be dissolved in lipiodol at 2 mg/ml on the day of procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Embospheres
Description: Embospheres are non-resorbable spherical microspheres (trisacryl gelatin) that are FDA-approved for embolization of hypervascular tumors.
Study: NCT02828709

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irreversible Electroporation
Description: Guided by CT and accompanied by an external spacer for fixation, needle electrodes will be placed. The amount of probes and probe placement will be attuned for specific tumour size and location, granting 15mm between the electrodes with an active tip length of 15mm. IRE pulses with pulse intensity of 1500 V/cm will be delivered in 90 consecutive pulses of 90µs.
Study: NCT03100630

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RO7239361
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RO7239361
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RO7239361
Description: Specified dose on specified days
Study: NCT01539915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCT194
Description: Topically applied BCT194 cream (0.5%)
Study: NCT05047003

Intervention type: DIAGNOSTIC_TEST
Intervention: EyeBOX Model EBX-4 (Portable version)
Description: The portable EyeBOX takes less than 4 minutes to complete and involves watching a video move around the perimeter of an LCD monitor positioned in front of the patient while a high-speed camera continuously records gaze positions. The Portable EyeBOX software detects subtle changes in eye movements consistent with concussion and calculates a BOX score.
Study: NCT00320112

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reciprocal Diabetes Peer Support Program
Description: participants are paired with another age-matched participation. Paired peer partners were encouraged to talk weekly using a telephone platform that recorded call frequency and duration and provided automated reminders promoting peer contact.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Nurse Case management
Description: patients are not paired in the NCM arm attended a 1.5 hour session to receive education on care manager services and diabetes educational materials and be assigned to a nurse care manager with whom they were encouraged to follow-up regularly.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: group outpatient counseling visits
Description: Participants in the peer group were also offered three optional 1.5 hour patient-driven group sessions at month 1, 3, and 6
Study: NCT02693210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Participants will receive 750 mg infusions of cyclophosphamide on Days 3 and 17

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Participants will receive \>= 10 mg/week methotrexate orally up to 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Participants will receive \>= 10 mg/week methotrexate orally up to 24 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Cyclophosphamide
Description: Participants will receive placebo in place of cyclophosphamide on Days 3 and 17

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Cyclophosphamide
Description: Participants will receive placebo in place of cyclophosphamide on Days 3 and 17

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Cyclophosphamide
Description: Participants will receive placebo in place of cyclophosphamide on Days 3 and 17

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Methotrexate
Description: Participants will receive weekly oral placebo in place of Methotrexate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Methotrexate
Description: Participants will receive weekly oral placebo in place of Methotrexate

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Rituximab
Description: Participants will receive placebo in place of rituximab on days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants will receive 1g infusions of rituximab on Days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants will receive 1g infusions of rituximab on Days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants will receive 1g infusions of rituximab on Days 1 and 15
Study: NCT04088760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCRαβ+/CD19+ depleted allogeneic hematopoietic stem cell transplant (HSCT)
Description: The majority of TCRαβ+ T cells and CD19+ B cells will be removed from the allogeneic graft utilizing the CliniMACS® immunomagnetic selection device (Miltenyi Biotec). The depletion process involves two phases; cell labeling (phase 1) and the automated immunomagnetic depletion process (phase 2). The CD34+ dose may be adjusted by the need to not exceed the TCRαβ+CD3+ dose threshold.
Study: NCT03488186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole Capsules
Description: 24 healthy volunteers will be recruited and randomized into 2 groups (12 for each). During the study session, subjects will receive T drug in group A or R drug in group B for 7 days in fasted condition.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole Capsules
Description: 24 healthy volunteers will be recruited and randomized into 2 groups (12 for each). During the study session, subjects will receive T drug in group A or R drug in group B for 7 days in fasted condition.
Study: NCT01492894

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporins/Tacrolimus
Description: Decrease the dose of calcineurin inhibitor by 1/2 and the drug level will be followed and adjusted to the target level of 50% of the previous levels

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Change from current calcineurin inhibitor to Sirolumus
Study: NCT02766075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised TAVR Exercise Program
Description: Individualized exercise program designed and implemented by licensed physical therapy clinicians in three 60-minute sessions per week for four weeks. Upon randomization, subjects in the Intervention Group will undergo an initial Dynamic Gait \& Balance Assessment by a licensed physical therapy clinician. The physical therapy clinician will use this assessment to design and implement an individualized STEP in three 60-minute sessions per week for four weeks. Subjects will proceed with their pre-TAVR testing in conjunction with the STEP sessions.
Study: NCT03095222

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: To be given as intravenous infusion. Ketamine infusions will be started at 5 mg/hr and can be increased by nursing staff based on patient-reported pain relief up to a maximum hourly rate of 20 mg/hr.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: To be given as intravenous infusion. Ketamine infusions will be started at 5 mg/hr and can be increased by nursing staff based on patient-reported pain relief up to a maximum hourly rate of 20 mg/hr.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioids
Description: Standard of care for pain management.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioids
Description: Standard of care for pain management.
Study: NCT02665013

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored
Description: Pregnant women will be recruited to the study. The intervention will be delivered to participants prior to the child's 2 month well child visit, when the child is between 4 and 6 months of age, and when the child is 10-12 months of age. The first intervention occurs at enrollment in the study. Participants in the tailored intervention arm will receive vaccine information tailored specific to her concerns and values at each intervention point.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Untailored
Description: Pregnant women will be recruited to the study. The intervention will be delivered to participants prior to the child's 2 month well child visit, when the child is between 4 and 6 months of age, and when the child is 10-12 months of age. The first intervention occurs at enrollment in the study. Participants in the untailored arm will receive vaccine information at each intervention time point, but it will not be tailored to her specific concerns.
Study: NCT01825993

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-BUPIVACAINE ; MORPHINE

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-BUPIVACAINE ; MORPHINE

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MORPHINE
Study: NCT01997203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: vitamin D was given to 50 patients (HCV under treatment)